OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial

OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial

Source: 
Drug Delivery Business News
snippet: 

OncoSec Medical (NSDQ:ONCS) expanded its relationship with Merck (NYSE:MRK) today, announcing a deal to combine its ImmunoPulse IL-12 device with Merck’s anti-PD-1 therapy, Keytruda, in a Phase II trial of patients with triple negative breast cancer.